Citation: G. Dranitsaris et al., Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate, ANTI-CANC D, 11(7), 2000, pp. 591-601
Authors:
Hoskins, P
Eisenhauer, E
Vergote, I
Dubuc-Lissoir, J
Fisher, B
Grimshaw, R
Oza, A
Plante, M
Stuart, G
Vermorken, J
Citation: P. Hoskins et al., Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study, J CL ONCOL, 18(24), 2000, pp. 4038-4044
Authors:
Goss, PE
Strasser, K
Marques, R
Clemons, M
Oza, A
Goel, R
Blackstein, M
Kaizer, L
Sterns, EE
Nabholtz, JM
De Coster, R
Crump, M
Abdolell, M
Qi, S
Citation: Pe. Goss et al., Liarozole fumarate (R85246): In the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer, BREAST CANC, 64(2), 2000, pp. 177-188
Authors:
Goss, PE
Oza, A
Goel, R
Nabholtz, JM
De Coster, R
Bruynseels, J
Reid, C
Wadden, N
Crump, M
Tye, LM
Citation: Pe. Goss et al., Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer, BREAST CANC, 59(1), 2000, pp. 55-68
Authors:
Wong, R
Milosevic, M
Sturgeon, J
Pintilie, M
Fyles, A
Levin, W
Rosen, B
Depetrillo, D
Oza, A
Manchul, L
Murphy, J
Chapman, W
Citation: R. Wong et al., Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: Results of a prospective treatment protocol, INT J RAD O, 45(3), 1999, pp. 657-665
Authors:
Ross, G
Malfetano, J
Clarke-Pearson, D
Oza, A
Gore, M
Beckman, R
Fields, S
Lane, S
Dane, G
Citation: G. Ross et al., IV topotecan (TOPT) in patients (Pts) who relapse following platinum(P)/paclitaxel(TX) treatment: subset analysis of a phase III trial, 7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, pp. 285-289